Sign In   |   Register
Menu

Summary of EAS 2019 Congress Maastricht, The Netherlands, May 26-29

This year’s Congress attracted more than 2,000 delegates from 70 countries, a reflection of the global presence of the EAS. Opening the Congress, EAS President Professor Lale Tokgözoğlu (Hacettepe University, Ankara, Turkey) highlighted the role of the Society in research, education and collaboration.

The new Joint Dyslipidaemia Guidelines with the European Society of Cardiology are eagerly anticipated later this year, in the light of recent findings from major trials of innovative therapies. Added to this, Professor Tokgözoğlu confirmed that three new EAS Consensus Panel publications are anticipated in the near future, focusing on 1) pathophysiological evidence for the causality of apolipoprotein B-containing lipoproteins, a much anticipated follow-up to the first low-density lipoprotein (LDL) causality statement,1 2) rare lipid disorders, and 3) a new approach to cardiovascular risk estimation. In addition, advanced lipid courses, courses in rare lipid disorders, and the EAS Academy are just some examples of the role of the EAS in education.

#EAS2019
Follow the Congress on Twitter or Facebook @eascongress  @EuropeanAtherosclerosisSociety

To the on site reports and photos from the meeting >>

To EAS 2019 and the full programme >>

The Congress App >>

The European Atherosclerosis Society FH Studies Collaboration and FH Europe announce partnership

One voice in Europe on FH

We are excited to announce a new collaboration between Familial Hypercholesterolaemia (FH) patient representative network, FH Europe, and the FH investigators from all over the world who work together as part of the EAS FH Studies Collaboration (FHSC).

FH continues to be a major global health problem, very common — worldwide, one in every 200‑500 people has FH — yet widely underdiagnosed and undertreated. Most people who have FH do not know they have it. These people have inherited high cholesterol, and are at risk for premature atherosclerosis and early cardiovascular events that are often fatal. But if FH is identified early, and effective treatment begun, individuals with FH can live long and healthy lives.

Through this collaboration FH Europe and the FHSC will speak withone voice on FH, and by linking FH patient groups with expert clinicians from all over the world, we will share globally established best practices that will mean more persons with FH are identified early and, once they are identified, a smoother pathway for the patient to referral and potentially life-saving treatment in the clinic.

We will work together on our common goals towards improving care for FH patients: working within the FH community with initiatives reducing gaps in knowledge, informing best practice, assisting in clinical trials design, and supporting clinical guidelines and development of policies; reaching outside the FH community by raising awareness of the burden of FH among healthcare professionals and policy-makers, and advancing global public policy on FH.

Lale Tokgozoglu
President, EAS

Kausik Ray
FHSC Lead
Alberico L. Catapano
FHSC Co-lead
Jules Payne
Chair, FH Europe
   
 

Read the full press release >>

Read more about EAS FH Studies Collaboration >>

Read more about FH Europe >>

From the EAS President:

Want to know more about our Society and current activities? Read the review and reflection on the progress we have made in the Society’s activities during 2018 and our plans for 2019 here.

Lale Tokgozoglu MD FACC FESC
President, European Atherosclerosis Society
Professor of Cardiology
Hacettepe University
Ankara-Turkey

Member sign in



Access the Society journals



Log in to access Atherosclerosis >>

Calendar more

17/06/2019 » 30/08/2019
Nominate a candidate for the Anitschkow Prize 2020

01/07/2019 » 31/10/2019
Submit you paper for the "Best Paper Award 2020"

03/09/2019
EAS Joint session with ESC - European Society of Cardiology

EAS Academy
EAS Journal
Become an EAS Member
Guidelines
Membership Software Powered by YourMembership  ::  Legal